TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CARISSA Trial - Multicenter Randomized Phase II Trial Comparing Post-operative Radiotherapy and Cisplatin Alone or in Combination With the EGFR Inhibitor ZD 1839 (Iressa) in Upper Aerodigestive Tract Carcinomas
Brief Summary: This trial will be an open multicentric randomized phase II study comparing post-operative radiotherapy + cisplatin associated or not with Iressa in upper aerodigestive tract carcinomas.


Options:
A: Arm Label: CETUXIMAB AND DASATINIB; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab, Drug: Dasatinib | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): CETUXIMAB AND DASATINIB | Intervention Type: DRUG; Name: Dasatinib; Assigned to Arm(s): CETUXIMAB AND DASATINIB
B: Arm Label: Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer); Type: EXPERIMENTAL; Interventions: Drug: erlotinib hydrochloride, Drug: cisplatin, Radiation: 3-dimensional conformal radiation therapy, Radiation: intensity-modulated radiation therapy, Procedure: quality-of-life assessment | Arm Label: Arm II (chemotherapy, radiotherapy); Type: ACTIVE_COMPARATOR; Interventions: Drug: cisplatin, Radiation: 3-dimensional conformal radiation therapy, Radiation: intensity-modulated radiation therapy, Procedure: quality-of-life assessment | Intervention Type: DRUG; Name: erlotinib hydrochloride; Assigned to Arm(s): Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer) | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer), Arm II (chemotherapy, radiotherapy) | Intervention Type: RADIATION; Name: 3-dimensional conformal radiation therapy; Assigned to Arm(s): Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer), Arm II (chemotherapy, radiotherapy) | Intervention Type: RADIATION; Name: intensity-modulated radiation therapy; Assigned to Arm(s): Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer), Arm II (chemotherapy, radiotherapy) | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer), Arm II (chemotherapy, radiotherapy)
C: Arm Label: postop chemoradio with cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Radiation: chemoradiotherapy with cisplatin | Arm Label: postop chemoradio (cisplatin)+gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Iressa (Gefitinib) | Intervention Type: DRUG; Name: Iressa (Gefitinib); Assigned to Arm(s): postop chemoradio (cisplatin)+gefitinib | Intervention Type: RADIATION; Name: chemoradiotherapy with cisplatin; Assigned to Arm(s): postop chemoradio with cisplatin
D: Arm Label: Afatinib (BIBW 2992); Type: EXPERIMENTAL; Interventions: Drug: Afatinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Afatinib; Assigned to Arm(s): Afatinib (BIBW 2992)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Larynx Preservation With Induction Chemotherapy (Cisplatin, 5FU, Docetaxel) Followed by Radiotherapy Combined With Either Cisplatin or Cetuximab in Laryngopharyngeal Squamous Cell Carcinoma - A Randomised Phase II Study
Brief Summary: Larynx preservation remains a very challenging approach in patients with larynx/pharynx cancer. A first attempt consisted of induction chemotherapy followed in good responders by irradiation. This approach allowed to preserve 60 % of the larynx without any significant difference in survival. The second attempt consisted of concurrent chemo-irradiation. This approach provided a higher larynx preservation rate but survival remained unchanged and mucosal toxicity was also higher. A third approach is currently under evaluation: induction chemotherapy followed by concurrent chemo-irradiation in good responders.


Options:
A: Intervention Type: DRUG; Name: XRP6976 (Docetaxel/Taxotere); Assigned to Arm(s): N/A
B: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: cisplatin, Drug: docetaxel, Drug: fluorouracil | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: cisplatin | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): Arm I | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm I | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Arm I
C: Arm Label: Cetuximab Plus Chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU) | Arm Label: Chemotherapy alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Platinum (Cisplatin or Carboplatin) + 5-FU | Intervention Type: DRUG; Name: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU); Assigned to Arm(s): Cetuximab Plus Chemotherapy | Intervention Type: DRUG; Name: Platinum (Cisplatin or Carboplatin) + 5-FU; Assigned to Arm(s): Chemotherapy alone
D: Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Radiotherapy 70 Gy, 35 fractions; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Proactive Cessation Intervention With Biomarker Feedback
Brief Summary: The goal of this study is to understand how information about smokers' health risks affects their attitudes, mood, and behavior.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: motivational counseling | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: placebo | Intervention Type: BEHAVIORAL; Name: motivational counseling; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: PA+ Smoking Cessation (LMPA); Type: EXPERIMENTAL; Interventions: Behavioral: PA+ Smoking Cessation (LMPA) | Arm Label: Standard Care Smoking Counseling (SCC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Care Smoking Counseling (SCC) | Intervention Type: BEHAVIORAL; Name: PA+ Smoking Cessation (LMPA); Assigned to Arm(s): PA+ Smoking Cessation (LMPA) | Intervention Type: BEHAVIORAL; Name: Standard Care Smoking Counseling (SCC); Assigned to Arm(s): Standard Care Smoking Counseling (SCC)
C: Arm Label: CBT+ Contact; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CBT+ Contact | Arm Label: CBT+ Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: CBT+ Exercise | Intervention Type: BEHAVIORAL; Name: CBT+ Contact; Assigned to Arm(s): CBT+ Contact | Intervention Type: BEHAVIORAL; Name: CBT+ Exercise; Assigned to Arm(s): CBT+ Exercise
D: Arm Label: Brief Advice; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Not On Tobacco (N-O-T) Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Not On Tobacco (N-O-T) Program | Arm Label: Quit & Fit; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Module, Behavioral: Not On Tobacco (N-O-T) Program | Intervention Type: BEHAVIORAL; Name: Physical Activity Module; Assigned to Arm(s): Quit & Fit | Intervention Type: BEHAVIORAL; Name: Not On Tobacco (N-O-T) Program; Assigned to Arm(s): Not On Tobacco (N-O-T) Program, Quit & Fit

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Proactive Cessation Intervention With Biomarker Feedback
Brief Summary: The goal of this study is to understand how information about smokers' health risks affects their attitudes, mood, and behavior.


Options:
A: Arm Label: CO reminder; Type: EXPERIMENTAL; Interventions: Behavioral: Informing surgical patients about CO monitoring | Arm Label: no CO reminder; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: a brief intervention recommending preoperative abstinence from smoking | Intervention Type: BEHAVIORAL; Name: Informing surgical patients about CO monitoring; Assigned to Arm(s): CO reminder | Intervention Type: BEHAVIORAL; Name: a brief intervention recommending preoperative abstinence from smoking; Assigned to Arm(s): no CO reminder
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: motivational counseling | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: placebo | Intervention Type: BEHAVIORAL; Name: motivational counseling; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: Personalized Risk Information; Type: ACTIVE_COMPARATOR; Interventions: Other: Personalized Heart Attack and Stroke Risk | Arm Label: Standard Education; Type: OTHER; Interventions: Other: Standard Education | Intervention Type: OTHER; Name: Personalized Heart Attack and Stroke Risk; Assigned to Arm(s): Personalized Risk Information | Intervention Type: OTHER; Name: Standard Education; Assigned to Arm(s): Standard Education
D: Arm Label: Spirometry and lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle counseling and spirometry | Arm Label: Lifestyle counseling; Type: NO_INTERVENTION; Interventions: Behavioral: Smoking cessation advice | Intervention Type: BEHAVIORAL; Name: Lifestyle counseling and spirometry; Assigned to Arm(s): Spirometry and lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Smoking cessation advice; Assigned to Arm(s): Lifestyle counseling

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Proactive Cessation Intervention With Biomarker Feedback
Brief Summary: The goal of this study is to understand how information about smokers' health risks affects their attitudes, mood, and behavior.


Options:
A: Arm Label: Fax to Quit plus Enhanced Academic Detailing (F2Q + EAD); Type: EXPERIMENTAL; Interventions: Other: Fax to Quit (F2Q) | Arm Label: Fax to Quit alone; Type: PLACEBO_COMPARATOR; Interventions: Other: Fax to Quit (F2Q) | Intervention Type: OTHER; Name: Fax to Quit (F2Q); Assigned to Arm(s): Fax to Quit alone, Fax to Quit plus Enhanced Academic Detailing (F2Q + EAD)
B: Intervention Type: BEHAVIORAL; Name: Financial incentives; Assigned to Arm(s): N/A
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Proactive Care; Type: EXPERIMENTAL; Interventions: Behavioral: Proactive Outreach with choice of telephone or in-person smoking cessation services | Intervention Type: BEHAVIORAL; Name: Proactive Outreach with choice of telephone or in-person smoking cessation services; Assigned to Arm(s): Proactive Care
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: motivational counseling | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: placebo | Intervention Type: BEHAVIORAL; Name: motivational counseling; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Herbal Alternatives for Menopause Symptoms: A Randomized Trial
Brief Summary: Surveys indicate that 25 to 33% of women have moderate to severe menopausal symptoms including hot flashes, night sweats, and disturbed sleep. The treatment of choice in the medical community for these symptoms is hormone replacement therapy, which is estrogen and sometimes progestin. Many women also use over-the-counter herbal remedies. However, less is known about how well these products work, or their safety. Few have undergone the kind of rigorous testing required of prescription drugs and little is known about their long-term effectiveness in relieving symptoms.

The purpose of this study is to compare several over-the-counter herbal remedies to hormone replacement therapy. Our primary aim is to look at the effects of these remedies on your self-reported menopausal symptoms. We will also be measuring their effects on other factors known to be affected by hormone replacement therapy: cholesterol, blood sugar, bone density, vaginal cell structure, and blood clotting.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Soy isoflavones | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Soy isoflavones | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Soy isoflavones; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Soy isoflavones; Assigned to Arm(s): 3
B: Intervention Type: DRUG; Name: Black cohosh; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Multibotanical preparation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Multibotanical preparation + dietary soy counseling; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Conjugated equine estrogen +/- medroxyprogesterone acetate; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Soy isoflavones | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Soy isoflavones; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIb, Partially Blind, Randomized, Placebo-controlled Study to Asses the Effect on Immunogenicity of Administration of Vaccine Without Buffering Agent and to Assess Heat Stability in Terms of Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Following a 0, 2 Month Schedule, in Healthy Infants Previously Uninfected With Human Rotavirus
Brief Summary: Rotavirus (RV) is the most important cause of acute gastroenteritis (GE) requiring hospitalization of infants and young children in developed and developing countries and can be a frequent cause of death in children less than 5 years of age. GSK Biologicals has developed a vaccine against human rotavirus gastroenteritis. In this study, the immunogenicity, reactogenicity and safety of the HRV vaccine will be evaluated when stored or reconstituted in circumstances different from the recommendations: i.e. when not reconstituted with a buffer or when stored for 7 days at 37°C before reconstitution. In addition, the effect of feeding will be explored for HRV vaccine reconstituted without buffer.


Options:
A: Arm Label: Rotarix 3-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Rotarix 2-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix 2-Dose Group, Rotarix 3-Dose Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group, Rotarix 2-Dose Group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Rotateq™ | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Intervention Type: BIOLOGICAL; Name: Rotateq™; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): 2
C: Arm Label: HIV-uninfected RotaTeq; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq | Arm Label: HIV-uninfected Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: HIV-infected RotaTeq; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq | Arm Label: HIV-1 infected Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: RotaTeq; Assigned to Arm(s): HIV-infected RotaTeq, HIV-uninfected RotaTeq | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): HIV-1 infected Placebo, HIV-uninfected Placebo
D: Intervention Type: BIOLOGICAL; Name: Live attenuated human rotavirus vaccine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity: 3 Consecutive Lots of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly at 0,1,6 Month Schedule in Healthy Females Aged 10-25 Years and Demonstrate Non-inferiority of Candidate HPV Vaccine Manufactured by Modified Production Process
Brief Summary: Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus or womb). This infection often goes away by itself, but if it does not go away (this is called persistent infection), it can lead in women over a long period of time to cancer of the cervix. If a woman is not infected by HPV, it is very unlikely that she will get cervical cancer. This study will evaluate the consistency of consecutive vaccine lots and the non-inferiority of modified manufacturing processes of GSK Biologicals HPV-16/18 vaccine and the vaccine safety, over 12 months, in young adolescents and women of 10-25 years of age at study start. Approximately 750 study subjects will receive different lots of the HPV vaccine administered intramuscularly according to a 0-1-6 month schedule.


Options:
A: Intervention Type: BIOLOGICAL; Name: HPV-16/18 L1/AS04; Assigned to Arm(s): N/A
B: Arm Label: Cohort A (Trial Cohort, Vaccinated during HPV-008); Type: N/A; Interventions: Procedure: Screening for cervical cancer | Arm Label: Cohort B1 + B2; Type: N/A; Interventions: Procedure: Screening for cervical cancer | Arm Label: Cohort C (Referent Cohort, Non-Vaccinated); Type: N/A; Interventions: Procedure: Screening for cervical cancer | Intervention Type: PROCEDURE; Name: Screening for cervical cancer; Assigned to Arm(s): Cohort A (Trial Cohort, Vaccinated during HPV-008), Cohort B1 + B2, Cohort C (Referent Cohort, Non-Vaccinated)
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Arm Label: Aluminium Hydroxide Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo control | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Placebo control; Assigned to Arm(s): Aluminium Hydroxide Group
D: Arm Label: Cervarix 1 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine 580299 | Arm Label: Cervarix 2 Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: GSK Biologicals' HPV vaccine 580299 | Arm Label: Cervarix 3 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine 580299 | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' HPV vaccine 580299; Assigned to Arm(s): Cervarix 1 Group, Cervarix 2 Group, Cervarix 3 Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Therapeutic and Biological Effects of High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in Schizophrenia
Brief Summary: The study is a prospective, randomized, double-blind sham-controlled study.


Options:
A: Arm Label: Low frequency left (LFL) sided rTMS; Type: EXPERIMENTAL; Interventions: Device: repetitive Transcranial Magnetic Stimulation | Arm Label: Priming stimulation; Type: EXPERIMENTAL; Interventions: Device: repetitive Transcranial Magnetic Stimulation | Arm Label: Sham Control; Type: SHAM_COMPARATOR; Interventions: Device: repetitive Transcranial Magnetic Stimulation | Intervention Type: DEVICE; Name: repetitive Transcranial Magnetic Stimulation; Assigned to Arm(s): Low frequency left (LFL) sided rTMS, Priming stimulation, Sham Control
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Repetitive transcranial magnetic stimulation | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Other: Sham repetitive transcranial magnetic stimulation | Intervention Type: OTHER; Name: Repetitive transcranial magnetic stimulation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Sham repetitive transcranial magnetic stimulation; Assigned to Arm(s): 2
C: Arm Label: Active rTMS; Type: ACTIVE_COMPARATOR; Interventions: Device: repetitive Transcranial Magnetic Stimulation | Arm Label: Sham rTMS; Type: SHAM_COMPARATOR; Interventions: Device: repetitive Transcranial Magnetic Stimulation | Intervention Type: DEVICE; Name: repetitive Transcranial Magnetic Stimulation; Assigned to Arm(s): Active rTMS, Sham rTMS
D: Arm Label: rTMS; Type: SHAM_COMPARATOR; Interventions: Procedure: rTMS, "repetitive transcranial magnetic stimulation", Other: rTMS | Intervention Type: PROCEDURE; Name: rTMS, "repetitive transcranial magnetic stimulation"; Assigned to Arm(s): rTMS | Intervention Type: OTHER; Name: rTMS; Assigned to Arm(s): rTMS

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Home-based Versus a Hospital-based Outpatient Pulmonary Rehabilitation Program in Patients With COPD: a Multicenter, Randomized Trial
Brief Summary: Short term efficacy of pulmonary rehabilitation for improving functional capacity and quality of life of chronic obstructive respiratory disease (COPD) patient is well known. However, there is an important gap between the scientific knowledge and the clinical use of pulmonary rehabilitation since a a very small number of patients benefit from this therapeutic intervention. We estimate that less than 1% of the 750 000 canadians suffering from COPD have access to a pulmonary rehabilitation program. We want to study the efficacy of a home-based rehabilitation program as a way to facilitate the access to rehabilitation.


Options:
A: Arm Label: COPD Web; Type: EXPERIMENTAL; Interventions: Behavioral: COPD Web | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: COPD Web; Assigned to Arm(s): COPD Web
B: Arm Label: Hospital-based; Type: EXPERIMENTAL; Interventions: Behavioral: Pulmonary rehabilitation (teaching and exercise) | Arm Label: Home-Based; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Pulmonary rehabilitation (teaching and exercise) | Intervention Type: BEHAVIORAL; Name: Pulmonary rehabilitation (teaching and exercise); Assigned to Arm(s): Home-Based, Hospital-based
C: Arm Label: Telemedicine training and counselling; Type: EXPERIMENTAL; Interventions: Other: Telemedicine training and counselling | Intervention Type: OTHER; Name: Telemedicine training and counselling; Assigned to Arm(s): Telemedicine training and counselling
D: Arm Label: COPD Telehealth Program; Type: EXPERIMENTAL; Interventions: Behavioral: Telehealth Program | Intervention Type: BEHAVIORAL; Name: Telehealth Program; Assigned to Arm(s): COPD Telehealth Program

Answer: B